Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022
Inhibikase Therapeutics (Nasdaq: IKT) will disclose its financial results for the full year ended December 31, 2021, on March 31, 2022. The announcement will be followed by a conference call and webcast on April 1, 2022, at 8:00 a.m. ET, where the company will provide a corporate update. Inhibikase is focused on developing therapeutics aimed at modifying the course of Parkinson's disease and related disorders, with its lead program targeting the disease both in the brain and gastrointestinal tract.
- Company's focus on Parkinson's disease treatments may attract investor interest.
- None.
BOSTON and ATLANTA, Mar. 25, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that it will report financial results for the full year ended December 31, 2021 on Thursday, March 31, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Friday, April 1, 2022, to provide a corporate update and review the financial results.
The conference call can be accessed by dialing 877-407-4018 (United States) or 201-689-8471 (International) with the conference code 13727872. A live webcast may be accessed using the link here, or by visiting the investors section of the Company's website at www.inhibikase.com. After the live webcast, the event will be archived on Inhibikase's website for approximately 90 days after the call.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, or MSA, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-report-full-year-2021-financial-results-on-march-31-2022-301510565.html
SOURCE Inhibikase Therapeutics, Inc.
FAQ
When will Inhibikase Therapeutics report its financial results for 2021?
What time is the Inhibikase Therapeutics conference call for financial results?
What is the stock symbol for Inhibikase Therapeutics?
What is the primary focus of Inhibikase Therapeutics?
